health economic evaluation
Navigating market access: Launch strategies and health economic modelling for medical devices – a live panel discussion
Discover how health economics can support successful Medical Device launch, proposition development, and market access. Join us live at 1:30pm (GMT) on Wednesday 19th March for an insightful journey into...
What does HEOR really mean in 2025?
Global healthcare systems are under unprecedented strain. As life expectancies rise and populations age, the proportion of people aged 60+ years is expected to soar. This both signals remarkable progress...
Health economics training unpacked: A conversation with the trainers
Did you know we offer a suite of education and training options? Our workshops, insight sessions, and training help Pharma and Medtech teams upskill in key HEOR disciplines and prepare...
Challenges for orphan medicines entering the European market
We explore the various challenges facing orphan medicines entering the European market and offer solutions to help improve patient access.
Mtech Access are exhibiting at ISPOR in Europe
• Mtech Access – Powered by Petauri™ are excited to be returning to ISPOR Europe this November. The team will be joined by colleagues from across Petauri, including Delta Hat...
Navigating US payer evidence needs to optimise market access
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How...
Best practice RWE approaches to support economic modelling for HTA
How can real-world evidence (RWE) support health technology assessment (HTA)? Join the live webinar on Thursday 3rd October at 1.00pm (BST), featuring panellists from Mtech Access, Arcturis, and Delta Hat.
Surrogate endpoints in HTA: Reflections on my HTAi panel discussion
Calum Jones (Associate Director – Health Economics, Mtech Access) shares his experience of speaking at the 2024 HTAi Annual Meeting. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health...
How does Genesis Research Group ‘Innovate differently’?
New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to 'Innovate differently' and transform the way they engage...
The role of economic evaluation in US healthcare
Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US. They highlight important considerations for companies seeking...
Innovative Trials opens first US office
We are incredibly excited to announce the opening of our very first US office! This is an incredible milestone towards our mission to accelerate clinical development. Read the full press...
Innovative Trials opens first US office
The leading global patient recruitment organisation has opened its first international office in the Raleigh, North Carolina